QQQ   430.82 (-0.06%)
AAPL   169.07 (-2.10%)
MSFT   415.14 (+0.36%)
META   500.34 (+0.02%)
GOOGL   154.59 (-0.17%)
AMZN   183.27 (-0.19%)
TSLA   156.07 (-3.35%)
NVDA   873.26 (+1.54%)
AMD   162.84 (+1.57%)
NIO   3.86 (-0.77%)
BABA   69.92 (-0.99%)
T   15.98 (-1.60%)
F   12.12 (-0.90%)
MU   121.02 (-0.29%)
GE   155.42 (+1.12%)
CGC   6.80 (-2.58%)
DIS   113.68 (+0.65%)
AMC   2.80 (+13.36%)
PFE   25.74 (-0.66%)
PYPL   63.57 (+0.09%)
XOM   118.23 (-1.21%)
QQQ   430.82 (-0.06%)
AAPL   169.07 (-2.10%)
MSFT   415.14 (+0.36%)
META   500.34 (+0.02%)
GOOGL   154.59 (-0.17%)
AMZN   183.27 (-0.19%)
TSLA   156.07 (-3.35%)
NVDA   873.26 (+1.54%)
AMD   162.84 (+1.57%)
NIO   3.86 (-0.77%)
BABA   69.92 (-0.99%)
T   15.98 (-1.60%)
F   12.12 (-0.90%)
MU   121.02 (-0.29%)
GE   155.42 (+1.12%)
CGC   6.80 (-2.58%)
DIS   113.68 (+0.65%)
AMC   2.80 (+13.36%)
PFE   25.74 (-0.66%)
PYPL   63.57 (+0.09%)
XOM   118.23 (-1.21%)
QQQ   430.82 (-0.06%)
AAPL   169.07 (-2.10%)
MSFT   415.14 (+0.36%)
META   500.34 (+0.02%)
GOOGL   154.59 (-0.17%)
AMZN   183.27 (-0.19%)
TSLA   156.07 (-3.35%)
NVDA   873.26 (+1.54%)
AMD   162.84 (+1.57%)
NIO   3.86 (-0.77%)
BABA   69.92 (-0.99%)
T   15.98 (-1.60%)
F   12.12 (-0.90%)
MU   121.02 (-0.29%)
GE   155.42 (+1.12%)
CGC   6.80 (-2.58%)
DIS   113.68 (+0.65%)
AMC   2.80 (+13.36%)
PFE   25.74 (-0.66%)
PYPL   63.57 (+0.09%)
XOM   118.23 (-1.21%)
QQQ   430.82 (-0.06%)
AAPL   169.07 (-2.10%)
MSFT   415.14 (+0.36%)
META   500.34 (+0.02%)
GOOGL   154.59 (-0.17%)
AMZN   183.27 (-0.19%)
TSLA   156.07 (-3.35%)
NVDA   873.26 (+1.54%)
AMD   162.84 (+1.57%)
NIO   3.86 (-0.77%)
BABA   69.92 (-0.99%)
T   15.98 (-1.60%)
F   12.12 (-0.90%)
MU   121.02 (-0.29%)
GE   155.42 (+1.12%)
CGC   6.80 (-2.58%)
DIS   113.68 (+0.65%)
AMC   2.80 (+13.36%)
PFE   25.74 (-0.66%)
PYPL   63.57 (+0.09%)
XOM   118.23 (-1.21%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apyx Medical Co. stock logo
APYX
Apyx Medical
$1.39
+0.7%
$1.87
$1.21
$7.97
$48.15M1.09150,085 shs22,857 shs
Accuray Incorporated stock logo
ARAY
Accuray
$2.24
-3.0%
$2.57
$2.22
$4.30
$222.14M1.44432,882 shs193,168 shs
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
$24.04
$24.02
$8.42
$24.25
$1.76B3.022.70 million shsN/A
RenovaCare, Inc. stock logo
RCAR
RenovaCare
$0.00
$0.00
$0.30
N/A1N/AN/A
The Westaim Co. stock logo
WEDXF
Westaim
$2.61
-0.8%
$2.66
$2.13
$2.99
$336.61M0.4635,644 shs27,840 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apyx Medical Co. stock logo
APYX
Apyx Medical
-5.48%-5.48%-22.91%-30.30%-54.00%
Accuray Incorporated stock logo
ARAY
Accuray
+1.32%-3.75%-11.49%-16.91%-23.00%
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
0.00%0.00%0.00%0.00%0.00%
RenovaCare, Inc. stock logo
RCAR
RenovaCare
0.00%0.00%0.00%0.00%-99.85%
The Westaim Co. stock logo
WEDXF
Westaim
-0.67%-0.76%-0.60%-4.74%+20.32%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apyx Medical Co. stock logo
APYX
Apyx Medical
4.3597 of 5 stars
3.54.00.04.23.31.70.6
Accuray Incorporated stock logo
ARAY
Accuray
3.6583 of 5 stars
3.51.00.04.62.11.70.6
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
RenovaCare, Inc. stock logo
RCAR
RenovaCare
N/AN/AN/AN/AN/AN/AN/AN/A
The Westaim Co. stock logo
WEDXF
Westaim
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apyx Medical Co. stock logo
APYX
Apyx Medical
3.00
Buy$6.17343.65% Upside
Accuray Incorporated stock logo
ARAY
Accuray
3.00
Buy$8.25268.30% Upside
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
N/AN/AN/AN/A
RenovaCare, Inc. stock logo
RCAR
RenovaCare
N/AN/AN/AN/A
The Westaim Co. stock logo
WEDXF
Westaim
N/AN/AN/AN/A

Current Analyst Ratings

Latest APYX, WEDXF, RCAR, GNMK, and ARAY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
2/13/2024
Accuray Incorporated stock logo
ARAY
Accuray
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
2/13/2024
Accuray Incorporated stock logo
ARAY
Accuray
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$9.00
(Data available from 4/16/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apyx Medical Co. stock logo
APYX
Apyx Medical
$52.35M0.92N/AN/A$0.78 per share1.78
Accuray Incorporated stock logo
ARAY
Accuray
$447.61M0.50N/AN/A$0.56 per share4.00
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
$88.02M19.96N/AN/A$0.21 per share114.48
RenovaCare, Inc. stock logo
RCAR
RenovaCare
N/AN/AN/AN/AN/AN/A
The Westaim Co. stock logo
WEDXF
Westaim
$8.63M39.00$1.40 per share1.87$3.95 per share0.66

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apyx Medical Co. stock logo
APYX
Apyx Medical
-$18.71M-$0.54N/AN/AN/A-35.75%-54.90%-28.41%5/9/2024 (Estimated)
Accuray Incorporated stock logo
ARAY
Accuray
-$9.28M-$0.15N/A16.00N/A-3.25%-28.11%-3.05%4/24/2024 (Estimated)
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
-$47.35M-$0.82N/AN/AN/A-16.95%-39.36%-13.02%N/A
RenovaCare, Inc. stock logo
RCAR
RenovaCare
-$4.47MN/A0.00N/AN/AN/AN/AN/AN/A
The Westaim Co. stock logo
WEDXF
Westaim
$183.98M$1.302.01N/A2,132.63%37.84%34.98%5/14/2024 (Estimated)

Latest APYX, WEDXF, RCAR, GNMK, and ARAY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/21/2024Q4 2023
Apyx Medical Co. stock logo
APYX
Apyx Medical
-$0.13-$0.19-$0.06-$0.10$14.40 million$14.66 million
1/31/202412/31/2023
Accuray Incorporated stock logo
ARAY
Accuray
-$0.05-$0.10-$0.05-$0.10$107.11 million$107.24 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apyx Medical Co. stock logo
APYX
Apyx Medical
N/AN/AN/AN/AN/A
Accuray Incorporated stock logo
ARAY
Accuray
N/AN/AN/AN/AN/A
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
N/AN/AN/AN/AN/A
RenovaCare, Inc. stock logo
RCAR
RenovaCare
N/AN/AN/AN/AN/A
The Westaim Co. stock logo
WEDXF
Westaim
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apyx Medical Co. stock logo
APYX
Apyx Medical
1.23
5.52
4.74
Accuray Incorporated stock logo
ARAY
Accuray
3.53
1.58
0.84
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
0.75
4.33
3.84
RenovaCare, Inc. stock logo
RCAR
RenovaCare
N/AN/AN/A
The Westaim Co. stock logo
WEDXF
Westaim
N/A
4.23
4.23

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Apyx Medical Co. stock logo
APYX
Apyx Medical
55.33%
Accuray Incorporated stock logo
ARAY
Accuray
64.08%
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
96.94%
RenovaCare, Inc. stock logo
RCAR
RenovaCare
N/A
The Westaim Co. stock logo
WEDXF
Westaim
N/A

Insider Ownership

CompanyInsider Ownership
Apyx Medical Co. stock logo
APYX
Apyx Medical
13.10%
Accuray Incorporated stock logo
ARAY
Accuray
3.78%
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
3.25%
RenovaCare, Inc. stock logo
RCAR
RenovaCare
0.86%
The Westaim Co. stock logo
WEDXF
Westaim
4.21%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Apyx Medical Co. stock logo
APYX
Apyx Medical
25234.64 million30.11 millionOptionable
Accuray Incorporated stock logo
ARAY
Accuray
1,02499.17 million95.42 millionOptionable
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
61873.09 millionN/AOptionable
RenovaCare, Inc. stock logo
RCAR
RenovaCare
187.35 million86.60 millionNot Optionable
The Westaim Co. stock logo
WEDXF
Westaim
7128.97 million123.54 millionNot Optionable

APYX, WEDXF, RCAR, GNMK, and ARAY Headlines

SourceHeadline
Analyzing GlucoTrack (NASDAQ:GCTK) & Westaim (OTCMKTS:WEDXF)Analyzing GlucoTrack (NASDAQ:GCTK) & Westaim (OTCMKTS:WEDXF)
americanbankingnews.com - April 8 at 1:17 AM
The Westaim Corporation Reports Q4 and Full Year 2023 ResultsThe Westaim Corporation Reports Q4 and Full Year 2023 Results
businesswire.com - March 27 at 4:25 PM
The Westaim Corporation Recognized on the TSX Venture 50 ListThe Westaim Corporation Recognized on the TSX Venture 50 List
businesswire.com - February 21 at 8:28 AM
Westaim Corp.Westaim Corp.
wsj.com - February 17 at 2:53 PM
DCK ELEVATES BILL BROWN TO PRESIDENTDCK ELEVATES BILL BROWN TO PRESIDENT
finance.yahoo.com - January 17 at 12:21 PM
Westaim (WEDXF) Price Target Increased by 6.07% to 3.93Westaim (WEDXF) Price Target Increased by 6.07% to 3.93
msn.com - November 27 at 5:22 PM
The Westaim GAAP EPS of $0.16The Westaim GAAP EPS of $0.16
seekingalpha.com - November 15 at 12:57 PM
The Westaim Corporation Reports Q3 2023 ResultsThe Westaim Corporation Reports Q3 2023 Results
finance.yahoo.com - November 14 at 4:56 PM
The Westaim GAAP EPS of $0.22, revenue of $35.9MThe Westaim GAAP EPS of $0.22, revenue of $35.9M
seekingalpha.com - August 15 at 9:22 PM
Westaim (WEDXF) Price Target Increased by 15.87% to 3.88Westaim (WEDXF) Price Target Increased by 15.87% to 3.88
msn.com - August 1 at 6:00 PM
Closing Bell: The Westaim Corp flat on Friday (WED)Closing Bell: The Westaim Corp flat on Friday (WED)
theglobeandmail.com - June 24 at 2:58 AM
Westaim Announces Pricing of Secondary Offering of Skyward Specialtys Common StockWestaim Announces Pricing of Secondary Offering of Skyward Specialty's Common Stock
technews.tmcnet.com - June 8 at 1:16 AM
Skyward Announces Pricing Of Secondary Offering Of 3.85 Mln Of Its Stock By Westaim At $23/shrSkyward Announces Pricing Of Secondary Offering Of 3.85 Mln Of Its Stock By Westaim At $23/shr
markets.businessinsider.com - June 8 at 1:16 AM
Westaim Announces Director ResignationWestaim Announces Director Resignation
technews.tmcnet.com - April 25 at 8:25 AM
Closing Bell: The Westaim Corp flat on Monday (WED)Closing Bell: The Westaim Corp flat on Monday (WED)
theglobeandmail.com - April 17 at 8:08 PM
The Westaim Corporation Recognized as Top Sector Performer with TSX Venture 50The Westaim Corporation Recognized as Top Sector Performer with TSX Venture 50
technews.tmcnet.com - February 21 at 9:55 AM
Westaim Third Quarter 2022 Earnings: US$0.12 loss per share (vs US$0.011 profit in 3Q 2021)Westaim Third Quarter 2022 Earnings: US$0.12 loss per share (vs US$0.011 profit in 3Q 2021)
nz.finance.yahoo.com - November 13 at 4:45 PM
WEDXF The Westaim CorporationWEDXF The Westaim Corporation
seekingalpha.com - October 1 at 5:43 PM
Is Westaim Corp (WEDXF) Stock a Good Investment?Is Westaim Corp (WEDXF) Stock a Good Investment?
aaii.com - September 6 at 10:24 AM
WEDXF.PK - Westaim Corp | Stock Price & Latest News | ReutersWEDXF.PK - Westaim Corp | Stock Price & Latest News | Reuters
reuters.com - September 3 at 9:42 PM
The Westaim Corporation Reports Q2 2022 ResultsThe Westaim Corporation Reports Q2 2022 Results
apnews.com - August 11 at 3:35 PM
The Westaim Corporation Reports Q1 2022 ResultsThe Westaim Corporation Reports Q1 2022 Results
finance.yahoo.com - May 17 at 11:18 AM
The Westaim Corporation Announces Dates for Q1 2022 Results, AGM, and Investor DayThe Westaim Corporation Announces Dates for Q1 2022 Results, AGM, and Investor Day
finance.yahoo.com - May 3 at 6:13 PM
Westaim earnings preview: what Wall Street is expectingWestaim earnings preview: what Wall Street is expecting
markets.businessinsider.com - April 14 at 10:42 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Apyx Medical logo

Apyx Medical

NASDAQ:APYX
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets in the United States and internationally. It operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). The company offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. Its Helium Plasma Technology products are marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It also develops and manufactures hand pieces for open and laparoscopic procedures; and OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Accuray logo

Accuray

NASDAQ:ARAY
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
GenMark Diagnostics logo

GenMark Diagnostics

NASDAQ:GNMK
GenMark Diagnostics, Inc., a molecular diagnostics company, engages in the developing and commercializing molecular panels based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company also offers Blood Culture Identification Gram-Positive and Negative panel, Blood Culture Identification Fungal Pathogen panel, and ePlex Gastrointestinal Pathogen Panel. In addition, it provides XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents to support a range of molecular tests with a workstation and disposable test cartridges. Further, the company offers diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, warfarin sensitivity test, thrombophilia risk test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test and eSensor SARS-CoV-2 Test. GenMark Diagnostics, Inc. sells its products through direct sales and technically specialized service organization in the United States, Europe, and internationally. The company was incorporated in 2010 and is headquartered in Carlsbad, California.
RenovaCare logo

RenovaCare

OTCMKTS:RCAR
RenovaCare, Inc., a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. RenovaCare, Inc. has a strategic collaboration StemCell Systems GmbH for isolating and spraying self-donated stem cells to regenerate tissues and organs. The company was formerly known as Janus Resources, Inc. and changed its name RenovaCare, Inc.,to RenovaCare, Inc. in January 2014. RenovaCare, Inc. was incorporated in 1983 and is based in Scottsdale, Arizona.
Westaim logo

Westaim

OTCMKTS:WEDXF
The Westaim Corporation is a private equity firm specializing in direct and indirect investments through acquisitions, joint ventures, secondary investments both direct and indirect, fund of fund investments, and other arrangements. For direct investments, the firm invests in early venture, mid venture, late venture, middle market, later stage, mature, emerging growth, PIPEs, and buyout transactions. For fund of fund investments, it seeks to invest in private equity funds, venture capital funds, and hedge funds. The firm seeks to provide long term capital to businesses operating in the global financial services industry. It typically acquires controlling interests in businesses. The firm seeks to acquire debt, equity, or derivative securities of both public and private companies. It invests with the objective of providing its shareholders with capital appreciation and real wealth preservation. The firm seeks to provide its portfolio companies with advisory services including, but not limited to, advice on capital allocation, financing strategy, performance measurement and merger and acquisition support. It also seeks to partner with like-minded providers of third party capital to help supplement the firm's own capital, when completing acquisitions. The firm generally seeks to hold its investments for seven to 15 years. The Westaim Corporation was founded in 1996 and is based in Toronto, Canada.